Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invitro InternationalIVRO +1.33% PE Ratio (TTM) is 13.58 as of Aug. 03, 2026, which is 32% below its 10-year median of 20.00. The stock has 1 warning sign investors should review. Among 95 Medical Diagnostics & Research companies, Invitro International ranks better than 84.21% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-08-03), Invitro International's share price is
$0.0679.
Invitro International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.01. Therefore, Invitro International's PE Ratio (TTM) for today is 13.58.
Good Sign:
Invitro International stock PE Ratio (=12.22) is close to 3-year low of 11.
The historical rank and industry rank for Invitro International's PE Ratio (TTM) or its related term are showing as below:
IVRO'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 11 Med: 20 Max: 110
Current: 13.58
During the past 9 years, the highest PE Ratio (TTM) of Invitro International was 110.00. The lowest was 11.00. And the median was 20.00.
IVRO's PE Ratio (TTM) is ranked better than 84.21% of 95
companies
in the Medical Diagnostics & Research industry
Industry Median: 32.15
vs IVRO: 13.58
During the past 9 years, Invitro International's highest 3-Year average EPS without NRI Growth Rate was 38.30% per year. The lowest was -73.00% per year. And the median was 35.20% per year.
Invitro International (OTCPK:IVRO) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Invitro International PE Ratio (TTM) Related Terms
Invitro International PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for Invitro International's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IVRO vs IDTA, PRPH, NSTM: PE Ratio (TTM) Comparison
For the Diagnostics & Research subindustry, Invitro International's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invitro International PE Ratio (TTM) vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invitro International's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Invitro International's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Invitro International's Share Price of today is $0.0679.
Invitro International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Invitro International (IVRO) has a PE Ratio (TTM) of 13.58 as of Aug. 03, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Invitro International and its competitors. This is 32% below median its historical median of 20.00. Over the past decade, Invitro International's PE Ratio (TTM) has ranged from 11.00 to 110.00. According to the industry distribution chart, Invitro International ranks #15 out of 95 companies in the Medical Diagnostics & Research industry, placing it in the top 15.8%.
Is Invitro International's PE Ratio (TTM) too high?
Invitro International's current PE Ratio (TTM) of 13.58 is 32% below median its 10-year median of 20.00. Over the past 10 years, this metric has ranged from a low of 11.00 to a high of 110.00. The Medical Diagnostics & Research industry median PE Ratio (TTM) is 32.15. Invitro International's value of 13.58 is 57.8% below this industry median. Based on the distribution chart, Invitro International ranks #15 out of 95 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Invitro International's PE Ratio (TTM) compare to IDTA and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, Invitro International ranks #15 out of 95 companies for PE Ratio (TTM). This places Invitro International in the top 16% of its industry — outperforming the majority of peers. The industry median PE Ratio (TTM) is 32.15. Invitro International's value of 13.58 is 57.8% below this benchmark. Historically, Invitro International's own PE Ratio (TTM) has ranged from 11.00 to 110.00 over the past decade. While the company's 10-year median is 20.00 vs. the industry median of 32.15, Invitro International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Medical Diagnostics & Research company?
The median PE Ratio (TTM) among Medical Diagnostics & Research companies is 32.15, based on 95 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invitro International's current PE Ratio (TTM) of 13.58 is 57.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Invitro International and its competitors. For the Medical Diagnostics & Research industry, the median PE Ratio (TTM) is 32.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invitro International's current PE Ratio (TTM) is 13.58, which is 32% below median its own 10-year median of 20.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invitro International stock overvalued right now?
Based on GuruFocus' analysis, Invitro International (IVRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 35.8% above its estimated fair value. The current PE Ratio (TTM) is 13.58, which is 32% below median its 10-year median of 20.00 and 57.8% below the Medical Diagnostics & Research industry median of 32.15. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Invitro International (IVRO), the current PE Ratio (TTM) is 13.58 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invitro International is a provider of non-animal testing methods. The company develops and commercializes test kits and laboratory services. Its testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its products and services include Irritection, Corrositex, and Lab Services. The company provides its products to various industries such as cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation. The majority of its revenue is generated from the United States and it also exports to other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVRO has been successfully added to your 
